

1 **TITLE PAGE**

2

3 **Age-Modulated Immuno-Metabolic Proteome Profiles of Deceased Donor**

4 **Kidneys Predict 12-Month Posttransplant Outcome**

5

6 **Authors:** Philip D Charles<sup>1,2†</sup>, Sarah Fawaz<sup>3,4\*</sup>, Rebecca H Vaughan<sup>3,4\*</sup>, Simon Davis<sup>2</sup>, Priyanka  
7 Joshi<sup>3</sup>, Iolanda Vendrell<sup>2</sup>, Ka Ho Tam<sup>5</sup>, Roman Fischer<sup>2</sup>, Benedikt M Kessler<sup>2</sup>, Edward J  
8 Sharples<sup>6</sup>, Alberto Santos<sup>1,7,8</sup>, Rutger J Ploeg<sup>3,4</sup>, Maria Kaiser<sup>3,4†</sup>

9

10 **Affiliations:**

11 <sup>1</sup>Big Data Institute, Nuffield Department of Medicine, University of Oxford; Oxford, United  
12 Kingdom.

13 <sup>2</sup>Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine,  
14 University of Oxford; Oxford, United Kingdom.

15 <sup>3</sup>Research and Development, NHS Blood and Transplant; Bristol & Oxford, United Kingdom.

16 <sup>4</sup>Nuffield Department of Surgical Sciences and Oxford Biomedical Research Centre, University  
17 of Oxford; Oxford, United Kingdom.

18 <sup>5</sup>Engineering Department, University of Oxford; United Kingdom.

19 <sup>6</sup>University Hospital Oxford; Oxford, United Kingdom.

20 <sup>7</sup>Center for Health Data Science, University of Copenhagen; Copenhagen, Denmark.

21 <sup>8</sup>Novo Nordisk Foundation Center for Protein Research, University of Copenhagen;  
22 Copenhagen, Denmark.

23 \*These authors contributed equally.

24

25 †Corresponding authors. Email: [philip.charles@ndm.ox.ac.uk](mailto:philip.charles@ndm.ox.ac.uk); [maria.kaisar@nds.ox.ac.uk](mailto:maria.kaisar@nds.ox.ac.uk)

26

27 **Keywords:**

28 Kidney transplantation, Machine Learning, Data Independent Acquisition, Proteomics, Donor  
29 Age, QUOD

30

31

## 32 ABSTRACT

33 **Background.** Organ availability limits kidney transplantation, the best treatment for end-  
34 stage kidney disease. Deceased donor acceptance criteria have been relaxed to include older  
35 donors with higher risk of inferior posttransplant outcomes. Donor age, although significantly  
36 correlates with transplant outcomes, lacks granularity in predicting graft dysfunction. Better  
37 characterization of the biological mechanisms associated with deceased donor organ damage and  
38 specifically predictive of transplant outcome in recipients is key to developing new assessment  
39 criteria for donor kidneys and developing function-preserving interventions.

40 **Methods.** 185 deceased donor pretransplant biopsies with clinical and demographic  
41 donor and recipient metadata were obtained from the Quality in Organ Donation biobank  
42 (QUOD), selected on the basis of 12-month paired posttransplant function and deep proteomic  
43 profiles acquired by mass spectrometry. Using a 2/3<sup>rd</sup>:1/3<sup>rd</sup> training:test data split, sampling  
44 equally across posttransplant function, we applied machine learning feature selection followed  
45 by protein-wise relaxed LASSO regression modeling, assessing the performance of the final set  
46 of protein models on the test data. Western blotting validated protein changes, and the biological  
47 relevance of the final set of protein models was externally validated by contextualization against  
48 a published dataset of human healthy and disease kidney transcriptomes.

49 **Results.** Our analysis revealed 144 proteins carrying outcome-predictive information, all  
50 of which showed donor-age modulated associations with posttransplant function, as opposed to  
51 age and protein/gene effects being independent terms. Observed associations with inflammatory,  
52 metabolic, protein processing and cell cycle pathways suggest biological targets for possible  
53 interventions pretransplant. Contextualization of our results against external spatial  
54 transcriptomic data suggest a sub-nephrotic spatial localization of the predictive signal.

55           **Conclusions.** Integrating kidney proteome information with clinical metadata enhances  
56 the resolution of donor kidney quality stratification, and the highlighted biological mechanisms  
57 open new research directions in developing predictive models and novel interventions during  
58 donor management or preservation to improve kidney transplant outcome.

59

## 60 **SIGNIFICANCE STATEMENT**

61 Currently, organ quality assessment pretransplant relies on key factors such as donor age or  
62 clinical information, these lack granularity in depicting graft susceptibility and capacity to  
63 function posttransplant. A high-resolution proteomic profiling of 185 pretransplant biopsies of  
64 kidneys with known posttransplant function and complete metadata was performed. Integration  
65 of donor kidney proteomes with 56 clinical metadata variables using regularized regression  
66 modelling resulted in enhancing the resolution of donor kidney quality stratification. Immuno-  
67 metabolic and catabolic processes contributed to donor kidney susceptibility and worse  
68 transplant outcomes in an age modulated pattern, validated by western blotting. Comparison of  
69 kidney proteomes with a recent transcriptomics dataset of healthy and diseased kidneys provide  
70 an additional special single cell resolution to the findings of this study.

71

72

## 73 INTRODUCTION

74 Kidney transplantation is the optimal treatment for end-stage kidney disease. Compared  
75 to dialysis, transplantation increases life-expectancy, improves quality of life and is cost-  
76 effective. Limited availability of suitable donor kidneys impedes treatment of chronic kidney  
77 disease, and often prolongs dialysis, increasing morbidity and mortality. Deceased donor organ  
78 shortages, living donation decline in some countries and emerging ageing populations drive  
79 increased utilization of older deceased donor kidneys, now comprising more than half of offered  
80 organs<sup>1,2</sup>.

81 Ageing associates with time-dependent decline of organ function, evidenced in kidneys  
82 by histologic lesions, such as tubular atrophy, interstitial fibrosis, glomerulosclerosis, and  
83 arteriosclerosis. Older kidneys demonstrate fewer functioning glomeruli, less renal mass,  
84 podocyte dysfunction, and impaired cellular repair<sup>3</sup>. Glomerular diseases are more common and  
85 associated with worse outcomes in older patients<sup>4</sup>. Age accelerates the transition from Acute  
86 Kidney Injury (AKI) to chronic injury<sup>5</sup> and is an independent risk factor of graft dysfunction and  
87 loss for deceased donor kidneys<sup>6</sup>; furthermore, older donors are more likely to suffer from  
88 additional risk factors such as diabetes, hypertension or cardiovascular disease.

89 Donor age is incorporated in clinical scoring algorithms to inform kidney allocation  
90 decisions<sup>7,8</sup>, but is insufficient to consistently predict transplant outcomes. Current front-line  
91 models incorporating further clinical factors such as terminal serum creatinine, history of  
92 hypertension and diabetes<sup>8,9</sup> show consistent performance across demographics but lack granular  
93 predictive accuracy<sup>10</sup>.

94 Molecular analyses of biopsies plausibly offer higher resolution assessment of organ  
95 state; but require ‘big picture’ understanding of mechanisms associated specifically with poor

96 outcome, rather than immediate (but potentially recoverable) acute injury. Deceased donors are  
97 frequently assessed as having sustained damage (i.e. AKI) based on serum creatinine levels<sup>11</sup>,  
98 however this metric poorly associates with longer term outcomes<sup>11-14</sup>.

99 Mass spectrometry (MS) proteomic studies can provide such a ‘big picture’, but have  
100 heretofore lacked cohort capacity to represent demographic diversity<sup>15</sup>. Advances in high-  
101 throughput techniques<sup>16</sup> now allow sensitivity and depth without sacrificing throughput capacity.  
102 Developments in machine learning and nonlinear regression analyses furthermore offer tools to  
103 extract maximal knowledge from limited size experimental cohorts, with applications in disease  
104 staging, disease recurrence prediction, treatment response monitoring, and biomarker  
105 identification<sup>17,18</sup>.

106 Integration of deep proteomic profiles with heterogenous clinical and demographic  
107 factors using modern statistical tools can empower the next steps toward precision medicine<sup>19</sup>.  
108 Here, we benefit from the granularity provided by our MS-based proteomic profiling to report  
109 age- and immunometabolism-related proteomic signatures in pre-implantation kidney biopsies  
110 associated with transplant outcomes.

111

## 112 **METHODS**

### 113 **Study Design**

114 Deceased donor pre-transplantation kidney biopsies (n=186; 1 sample excluded during  
115 data processing) were obtained from the Quality in Organ Donor (QUOD) biobank, a national  
116 multi-center UK wide bioresource of deceased donor clinical samples acquired during donor  
117 management and organ procurement. Biopsies were obtained from Donation after Brain Death

118 (DBD) donors and Donation after Circulatory Death (DCD) donors at the back table immediately  
119 after kidney procurement.

120 Selection of biopsies was based on paired 12-month post-transplant outcomes. To  
121 minimize the impact of recipient factors, we only included kidneys for which the contralateral  
122 kidney was transplanted with similar outcome. Kidneys were selected to cover the outcome  
123 continuum i.e. the range of estimated Glomerular Filtration Rate (eGFR) in the recipient at 12  
124 months posttransplant (henceforth, 'eGFR12'), from primary non-function to eGFR>80  
125 ml/min/1.73 m<sup>2</sup>, excluding pediatric donors. Samples were linked to corresponding donor and  
126 recipient demographic and clinical metadata, provided by NHS Blood and Transplant National  
127 Registry.

## 128 **Study Approval and Ethics statement**

129 Informed consent from donor families was obtained prior to sample procurement.  
130 Collection of QUOD samples and research ethics approval was provided by QUOD  
131 (NW/18/0187).

## 132 **Protein Extraction from Renal Tissue Specimens**

133 Deceased donor biopsies were procured, handled and stored according to consistent,  
134 predefined collection protocols designed to minimize pre-analytical variability. Donor kidney  
135 biopsies were collected ex situ immediately after flush-out and procurement of the kidney in the  
136 donor hospital on the back-table. Biopsies were obtained from the upper pole of the donor kidney  
137 cortex during back table preparation, using a 23mm needle biopsy gun. The obtained biopsies  
138 were divided in two, with one half stored in RNAlater (Thermo Scientific, Illinois, USA), then  
139 liquid nitrogen and the other half stored in formalin.

140 RNAlater biopsy samples were homogenized in RIPA buffer (89900, Thermo Scientific,  
141 Illinois, USA) with protease and phosphatase inhibitor cocktail (1861280, Thermo Scientific,  
142 Illinois, USA) using a bead beater (Biorad, Hertfordshire, UK) at 6500rpm for three cycles of 40  
143 seconds with intermediate cooling on wet ice between cycles. Biopsy protein concentration was  
144 determined using a Pierce Bicinchoninic Acid protein assay kit (23227 Thermo Scientific,  
145 Illinois, USA).

### 146 **In-Solution Trypsin Digestion**

147 50 µg of protein homogenates were prepared. Disulfide bonds were reduced by adding  
148 200 mM of DTT (Sigma) to a final concentration of 5 mM for 60 mins at room temperature. Free  
149 cysteine residues were alkylated by adding 200 mM of iodoacetamide (Sigma) to a final  
150 concentration of 20 mM and incubated for 60 mins at RT in the dark.

151 The samples were topped up to 200 µl with 6 M urea, 100 mM TrisHCl pH 8.5.  
152 Methanol/chloroform protein precipitation was used to remove detergents before tryptic  
153 digestion. In brief, 600 µl of Methanol and 150 µl of Chloroform were added and mixed. Then  
154 450 µl of MilliQ-H<sub>2</sub>O was added and then centrifuged for 1min at 12,000 g. The upper aqueous  
155 layer was carefully removed without disturbing formed protein pellets between layers and 450 µl  
156 of Methanol was added and then centrifuged at 12,000 g for 5 min. The supernatant was removed  
157 and the protein pellets resuspended in 50 µl of 6 M Urea, 100 mM TrisHCl, pH 8.5. Urea  
158 concentration was reduced to 1 M by adding 250 µl of MillQ-H<sub>2</sub>O. Samples were digested at 37  
159 °C overnight with Trypsin added at a 1:50 ratio (trypsin:protein). Tryptic peptides were acidified  
160 and purified using Sep-Pak C18 cartridges (WAT020515, Waters, Wilmslow, UK) and dried by  
161 Speed Vac centrifugation. Pellets were resuspended in 80 µl of resuspension buffer A (98 %  
162 MilliQ-H<sub>2</sub>O, 2 % acetonitrile 0.1 % formic acid) for LC-MS/MS analysis.



## 163 **Mass Spectrometry Analysis**

### 164 *Generation of Fractionated Pool for Spectral Library Reference*

165 A highly fractionated spectral library was generated as a standard reference for the  
166 subsequent analysis of individual samples. To create this spectral library, a pool sample was  
167 prepared by combining 2  $\mu$ l of each tryptic digest sample prepared above. Fractionation of the  
168 pooled sample was performed using offline high-pH reverse-phase HPLC on an XBridge BEH  
169 C18 XP column (3  $\times$  150 mm, 2.5  $\mu$ m pore size, Waters no. 186006710) over a 100-minute  
170 gradient (Buffer A: water, pH10 with ammonium hydroxide. Buffer B: 90 % acetonitrile, 10 %  
171 water, pH10 with ammonium hydroxide) with fractions collected every 2 minutes. The fractions  
172 of the pool sample for the spectral library were analyzed by nanoLC-MS/MS using a Dionex  
173 Ultimate 3000 using a 75  $\mu$ m  $\times$  500 mm (2  $\mu$ m particle size) C18 EASY-Spray column at 250  
174 nL/min (Thermo Scientific), coupled to an Orbitrap Fusion Lumos mass spectrometer. Peptides  
175 were separated using a 60-minute linear gradient from 2-35 % buffer B (Buffer A: 5 % DMSO,  
176 0.1 % formic acid in water. Buffer B: 5 % DMSO, 0.1 % formic acid in acetonitrile). The  
177 samples were analyzed on the mass spectrometer in Data-Dependent Acquisition mode. MS1  
178 scans were acquired in the Orbitrap with an m/z range of 400 – 1500 m/z at a resolution of  
179 120,000 and an AGC target of  $4 \times 10^5$ . Precursors between charge states 2+ and 7+ were selected  
180 for HCD fragmentation using the Advanced Precursor Determination option with an intensity  
181 threshold of  $2.5 \times 10^4$ . Selected precursors were isolated using the quadrupole with a 1.6 m/z  
182 isolation window and fragmented using HCD with a normalized collision energy of 30%. MS2  
183 spectra were acquired in the Orbitrap using a resolution of 30,000, a maximum injection time of  
184 54 ms and an AGC target of  $5 \times 10^4$ .

### 185 *LC-MS/MS Analysis of Individual Biological Samples*

186 The individual samples were analyzed on the same nanoLC-MS/MS system as above. A  
187 45-minute linear gradient was used from 2-35 % buffer B with the same buffer composition as  
188 above. In contrast to the pool samples, the individual samples were analyzed using the SWATH  
189 DIA method<sup>16</sup>. The sample analysis order was randomized, and analyses of aliquots of the  
190 pooled sample used for library generation were scheduled every 20 runs throughout the sequence  
191 as a quality control. MS1 scans were acquired in the Orbitrap with an m/z range of 350 – 1650  
192 m/z at a resolution of 120,000, an AGC target of  $4 \times 10^5$  and a 3 second cycle time. MS2 scans  
193 were then acquired in stepped isolation windows with a 1 Th overlap between each window; first  
194 from 350-380 m/z up to 930-960 m/z in increments of 30 Th (i.e. 21 scans with midpoints of  
195 365, 394 ... 916, 945), followed by a 100 Th window scan of 959-1059 m/z and a 592 Th scan of  
196 1058-1650 m/z.

197 Fragmentation of these windows was performed using a normalized collision energy of 25 %  
198 with a stepped collision energy of 10 %. MS2 spectra were acquired in the Orbitrap using a  
199 resolution of 30,000, a maximum injection time of 54 ms, an AGC target of  $5 \times 10^4$  and a scan  
200 range of 360-1650 m/z.

## 201 **Western Blot Validation**

202 Samples were compared as 5 Upper Tertile (UT) versus 5 Lower Tertile (LT) within a  
203 single age category (younger; total n=20, or older; total n=20) on each gel. Kidney homogenates  
204 at  $1 \mu\text{g}/\mu\text{L}$  of protein were denatured at  $90^\circ\text{C}$  in Laemmli buffer and separated using 4-12% pre-  
205 cast Bis-Tris gels (Thermo Fisher Scientific, Massachusetts, USA) in the case of VTN and  
206 APOE western blots and 16% pre-cast Tricine gels (Thermo Fisher Scientific, Massachusetts,  
207 USA) in the case of PREB and CST3 western blots, in both cases using MOPS running buffer  
208 and followed by transfer onto a PVDF membrane (Thermo Fisher Scientific, Massachusetts,

209 USA). Membranes were then blocked in Intercept (TBS) Blocking Buffer (LiCOR P/N 927-  
210 60001) and incubated with primary antibodies overnight at 4 °C. Antibodies used were rabbit  
211 polyclonal anti-PREB (Thermo Fisher Scientific PA5-53125), mouse polyclonal anti-Vitronectin  
212 (R&D, MAB2349), rabbit monoclonal anti-APOE (16H22L18) (Thermo Fisher Scientific,  
213 701241), rabbit monoclonal anti-CST3 (D6U3E) (Cell Signaling Technology, 24840) and  
214 mouse monoclonal anti- $\beta$ -actin (Sigma, A5316) for protein normalization. The membranes were  
215 then incubated in species appropriate secondary antibodies (RDye® 800CW Goat anti-Mouse  
216 IgG Secondary Antibody and IRDye® 680RD Goat Anti-Rabbit IgG Secondary Antibody,  
217 LiCOR, USA). Finally, blots were imaged using the LI-COR Odyssey system (LiCOR,  
218 Nebraska, USA). Analysis and quantification were performed using LiCOR Image Studio  
219 (Version 2.2). Protein expression was normalized against  $\beta$ -actin and the fold change was  
220 calculated relative to the per-gel mean value of the Upper Tertile group. For each protein, fold  
221 changes relative to UT were combined across all gels within each age category, log<sub>2</sub>  
222 transformed, and the difference between UT and LT calculated by t-testing without assumption  
223 of equal variance.

## 224 **Statistical Analyses**

### 225 *Proteomic Data Processing*

226 Both the DDA fractionated pools and all SWATH samples and pool data were analyzed  
227 simultaneously using DIA-NN v1.7.12<sup>20</sup>. MS/MS spectra from the DDA pools were searched  
228 against UniProt Reference *Homo sapiens* database (retrieved 15/10/2020) with default settings,  
229 including 1 missed cleavage, oxidation of methionine as a variable modification and  
230 carbamidomethylation of cysteine as a fixed modification, to generate a spectral library. This

231 was then cross referenced against the SWATH data to quantify peptides, and thus proteins,  
232 within each SWATH sample and pool run. Precursor FDR was set to 1%.

233 Subsequent analysis of the DIA-NN output and integration with the clinical data was  
234 performed in R v4.0.2. One sample had extremely low average intensity and more than 15%  
235 missing values, so was eliminated from the analysis. Across the remaining 185 samples and  
236 pools, proteins with more than 50% missing values were eliminated. Intensity values were  
237 transformed by VSN (R package ‘vsn’<sup>21</sup>), and the remaining missing values were imputed by a  
238 k-nearest neighbor approach (R package ‘impute’<sup>22</sup>).

### 239 *Clinical Variable Preprocessing*

240 Clinical variables were subdivided into Donation after Brain Death (DBD)-specific  
241 variables, Donation after Cardiac Death (DCD)-specific variables and jointly applicable  
242 variables (see annotation, Supplementary Table 1). DBD- and DCD-specific variables were  
243 considered for the purposes of assessing correlation with outcome but were not considered for  
244 statistical analyses applied to the full dataset.

245 For significance testing of outcome differences between donor and recipient  
246 characteristics, and for all modelling, eGFR values for both donor measurements and recipient  
247 measurements at 12-month post-transplantation were stratified into tertiles - Lower Tertile (UT;  
248  $eGFR < 40$ ), Intermediate Tertile (IT;  $40 \leq eGFR < 60$ ) and Upper Tertile (UT;  $eGFR \geq 60$ )  
249 based on their distribution. Missing values in the continuous and tertile-stratified forms of the  
250 variables were imputed for each sample by finding the ‘set of neighbors’ by 3-month eGFR, i.e.  
251 the 10 samples with the closest recipient eGFR at 3 months posttransplant, then taking the mean  
252 eGFR<sub>12</sub> (ignoring any missing values) within that set of neighbors.

253 We curated the non-DBD/DCD specific clinical variables to remove those inappropriate  
254 for modelling (single-instance categories, variables which duplicated another variable in  
255 different units); the final list is given in Supplementary Table 2. HLA mismatches were modelled  
256 as ‘Match Grade’ with levels None; no mismatches, Favorable; no DR and one or fewer B  
257 mismatches, and Non-Favorable; at least one DR or two B mismatches (Supplementary Figure  
258 S2 and Supplementary Table ST1).

259 For curated clinical variables, missing values were imputed for each sample in a similar  
260 manner. A set of neighbors was built by finding the 10 samples with the smallest Gower’s  
261 distance across all variables (multiple data types). We then took a relevant summary statistic of  
262 the non-missing values within the set of neighbors for each imputed value. For numeric values,  
263 the mean was taken. For categorical values, the most frequent category across the whole dataset  
264 was taken, breaking ties by iteratively shrinking the set of neighbors by removing the most  
265 distant from the sample to be imputed, until there was a single most frequent category.

### 266 *Outcome Subgroup Comparison*

267 Differences between outcome subgroups within DBD and DCD donor types (separately)  
268 were tested using Fisher’s exact test for categorical variables and t-tests for numeric variables as  
269 appropriate.

270 Clinical variable association was calculated depending on the type of each variable in  
271 pairwise comparisons. Numeric-numeric comparisons were by Pearson’s  $r$ . Numeric-categorical  
272 comparisons were by the square root of the proportion of variance explained ( $\eta$ ) from an  
273 ANOVA model where the numeric variable was taken as the response. Categorical-categorical  
274 comparisons were by Cramér’s  $V$ . Hierarchical clustering was performed using the single-linkage  
275 method to avoid composition of comparison types.

276           The proteomic and clinical data were matched in R by sample identifier. Based on an  
277 initial scree plot of the variance distribution, unsupervised clustering of the proteomic data was  
278 performed by k-means clustering with k=4. The number of initial random centroids and the  
279 maximum number of iterations were both set to 10.

#### 280 *Training and Test Data Split*

281           We split our data into a training and test sets, sampling equally across stratified eGFR. Of  
282 the 185 samples, 2/3 were used for training ('training set', 118 kidneys), and 1/3 were used for  
283 testing ('test set', 61 kidneys). Six paired kidneys (3 pairs) were reserved from both sets and used  
284 to assess MS and model performance ('QC set', 6 kidneys).

#### 285 *Machine Learning Feature Selection*

286           Using sample assigned to the training dataset, we modelled the combined dataset of all  
287 protein abundance data plus the curated donor clinical variables (Supplementary Table S2)  
288 against ranked 12 month posttransplant eGFR, using Prediction Rule Ensemble (PRE) modelling  
289 (R package 'pre'<sup>23</sup>). We used the 'gpe' function allowing linear fits, decision tree fits and  
290 multivariate adaptive regression spline fits (via R package 'earth'<sup>24</sup>) to be considered for each  
291 ensemble. Decision tree learning was set to be 'random forest'-like, with 500 initial trees  
292 generated and boosting disabled to allow parallel processing. Other settings (including tree  
293 pruning and the parameters for linear and spline fits) were left as default; tree depth was  
294 therefore limited to the default 3 decision levels. Ensemble modelling was performed in an  
295 iterative manner. At each stage, modelling was performed on the set of predictors that excluded  
296 proteins listed in the final ensemble of all previous models. Clinical variables were never  
297 excluded. Modelling was repeated for 2000 iterations and all proteins appearing in any rule

298 ensemble, or with high correlation (Pearson's  $r > 0.65$ ) to any of these candidates, were selected  
299 for further analysis.

### 300 *Regression Modelling*

301 Based on the outcome of feature selection, we used regularized regression (relaxed  
302 LASSO, package 'glmnet', using the cv.glmnet function with 20-fold cross validation, selecting  
303 as the final model the model that maximized the shrinkage parameter lambda such that it was  
304 within 1 standard error of the lambda value that had the smallest cross-validation error, i.e. the  
305 'lambda.1se' model) to regress each protein, donor age and protein:age terms against linearized  
306 outcome, defined as the proportion of eGFR12 values in the NHS Blood and Transplant National  
307 Registry between 2016 and 2021 inclusive (6 years) that were less than the observed eGFR12  
308 (i.e. a normalization to population distribution quantile). An independent age-only model was  
309 also fit against the training dataset using the same parameters. For each protein model and the  
310 age-only model we calculated the prediction root-mean-square error (RMSE). Proteins with a  
311 higher RMSE than the independent donor age model, or whose model did not retain either the  
312 protein or protein:age term were discarded.

### 313 *Functional Network Analysis*

314 The final list of proteins resulting from regression modelling was queried using the  
315 Enrichr platform (R package 'enrichR'<sup>25</sup>) against the Reactome 2022 database. Annotation term  
316 assignments were filtered at 5% FDR. From the set of candidates with at least one assigned term  
317 across all three databases, a connection graph was generated (R package 'igraph'<sup>26</sup>) with nodes  
318 representing proteins and edges representing shared annotation terms. Nodes (proteins) were  
319 clustered using the walktrap community detection algorithm<sup>27</sup> as implemented in igraph. Within-  
320 community enrichment for annotation terms was calculated by Fisher's exact test.

### 321 *Age-Protein-Outcome Clustering*

322 For each protein, eGFR12 was predicted using the corresponding relaxed LASSO model  
323 for donor ages 20,21,22...80 and protein quantiles 0,0.01,0.02...1, resulting in a 61x101 matrix.  
324 Matrix-matrix distances were computed using the Frobenius distance (R package  
325 ‘StatPerMeCo’<sup>28</sup>), and proteins were clustered according to these pairwise distances by  
326 hierarchical clustering.

### 327 *Spatial Correlation Analysis*

328 Processed, normalized AKI and CKD spatial scRNA-seq expression data generated by  
329 Lake *et al.*<sup>29</sup> were obtained from CELLxGENE  
330 (<https://cellxgene.cziscience.com/collections/bcb61471-2a44-4d00-a0af-ff085512674c>).  
331 Proteins identified by feature selection and LASSO regression filtering were matched to the  
332 expression dataset by the ‘Genes’ column in the DIA-NN output. AKI:CKD correlation in  
333 matched versus unmatched genes in each characterized spatial location was compared using the  
334 approach described by Fisher<sup>30</sup> (R package ‘cocor’<sup>31</sup>).

335

## 336 **RESULTS**

### 337 **Selected Samples were Demographically Balanced Across Outcome Strata**

338 Samples were selected to provide a balanced representation of the UK donor population  
339 (Table 1) and reproduced generally observed trends in terms of the correlation between eGFR12  
340 and clinical variables; we found the strongest associations were donor age (Pearson’s  $r=-0.52$ ),  
341 and recipient age ( $r=-0.28$ ) (Supplementary Figure S1).



342 For an interpretable analysis of key clinical factors, we considered our samples by  
343 eGFR12 stratum Lower Tertile (LT; eGFR12 < 40), Intermediate Tertile (IT; 40≤eGFR12<60),  
344 and Upper Tertile (UT; eGFR12≥60) all units ml/min/1.73 m<sup>2</sup> (Figure 1). We investigated  
345 associations between clinical variables and stratified eGFR12 subgroups within each donor type,  
346 and between donor types within stratified eGFR12 subgroups (Supplementary Table ST1); the  
347 only variables with significant difference between outcome groups across donor types were the  
348 UK Kidney Donor Risk Index; UKKDRI<sup>8</sup> (ANOVA F-test; DBD: p=1.298e-6; DCD: p=3.946e-  
349 7), donor age (ANOVA F-test; DBD: p=1.253e-9; DCD: p=1.196e-7), histories of hypertension  
350 (ANOVA F-test; DBD: p=0.0020; DCD: p=0.1069). Histories of diabetes (ANOVA F-test;  
351 p=0.6188; DCD: p=0.2348) and terminal serum creatinine levels (ANOVA F-test; DBD:  
352 p=0.6972; DCD: p=0.6448) were similar across outcome subgroups although the latter was  
353 higher in DBD than in DCD in the UT group (t-test; p=0.0443).

### 354 **Integration of Kidney Proteomes with Clinical Metadata by Rule Ensemble and Regression** 355 **Modelling Identifies Outcome-Associated Proteins**

356 Proteomic analysis quantified 2984 protein groups with 50% or less missing values (out  
357 of 7790 identified protein groups in total) over 185 samples and 20 interspersed sample pools  
358 (Supplementary Figure S2A). Analysis of sample pools showed minimal sample acquisition-  
359 related variance (squared mean pairwise Z-corrected Pearson's  $r=0.94$ ). The 3 pairs of kidneys  
360 showed high correlation of protein intensity values between donor pairs (Pearson's  $r=0.71$ ,  $0.92$   
361 and  $0.91$ ; Supplementary Figure S2B).

362 We initially explored the proteomic data using Principal Component Analysis (PCA) to  
363 find underlying linear trends. Sample variance concentrated in the first two principal components  
364 (PC1: 20.01%; PC2: 13.38%; Figure S3). K-means clustering identified 4 distinct clusters

365 (Figure S3; Figure S4A) which associated with donor type, with a preponderance of DBD  
366 samples towards Cluster 2 and a preponderance of DCD samples towards Cluster 4 (Figure S4B,  
367 upper left panel;  $p=0.0235$ ), but did not associate strongly with recipient eGFR ( $p=0.4134$ ),  
368 donor eGFR ( $p=0.1684$ ), or donor age ( $p=0.7907$ ) (Figure S4B, upper middle, upper right and  
369 lower left panels). There was a weakly significant association between cluster membership and  
370 donor BMI ( $p=0.0350$ ) and with donor serum creatinine ( $p=0.0326$ ) (Figure S4B, lower middle  
371 and lower right panels).

372 To assess individual protein relationships with outcome, we adopted a descriptive  
373 modelling approach, using a subset of our data ('training set'; 2/3 of data) to find protein models  
374 which predicted eGFR<sub>12</sub> better than donor clinical data alone, then assessing model performance  
375 against unseen (i.e. held out) test data ('test set', 1/3 of data). Six of the kidneys analyzed (3  
376 pairs) were pairs from the same donor; these were reserved from both training and test data for  
377 quality control ('QC set', 6 kidneys). To create our train/test split, we randomly selected equal  
378 numbers of samples for the training set within each of the eGFR<sub>12</sub> strata described above, to  
379 sample equally across outcome range.

380 To identify possible outcome-associated proteins, relevant clinical variables and potential  
381 protein-clinical variable interactions, we used iterative Prediction Rule Ensembles<sup>23</sup> (PRE)  
382 learning on our training set to select features among the set of quantified proteins and donor  
383 type-independent donor clinical variables. Briefly, PRE identifies a minimal ensemble of  
384 explanatory rule (functions of variables) for a given response (here, ranked eGFR<sub>12</sub>) allowing  
385 for nonlinear associations and variable interactions. To build a catalog (rather than minimal set)  
386 of explanatory proteins, we repeated our analysis 2000 times, removing proteins identified in the  
387 rule ensemble at each iteration from the dataset for future iterations, retaining clinical variables.

388 This process generated 195 candidate proteins; we further supplemented this list with proteins  
389 that had high correlation (Pearson's  $r > 0.65$ ) with any of those candidates; bringing the final list  
390 up to 255 candidates.

391 The only donor clinical variable term to feature consistently in rule ensembles was donor  
392 age, appearing in all 2000 ensembles generated. We individually tested each protein candidate  
393 for association with outcome, including protein, donor age, and age:protein interaction terms  
394 using LASSO regression<sup>32</sup> to aim for the simplest explanatory models (i.e. that include only the  
395 minimum necessary terms). To ensure models would generalize beyond our data, for the final  
396 modelling we linearized the eGFR12 measurement against UK NHS Blood and Transplant  
397 National Registry data. We discarded candidates whose model discarded both the protein and  
398 age:protein terms, or had a higher root-mean-square error (RMSE) of prediction than a model  
399 built with donor age alone.

400 After filtering we had identified 144 proteins which associated with outcome  
401 (Supplementary Table 2). The mean RMSE of our protein models was 25.76 ml/min/1.73m<sup>2</sup> in  
402 our training data, and fell slightly to 22.25 ml/min/1.73m<sup>2</sup> in our test data, indicating the models  
403 were not over-fit (Supplementary Figure S5).

## 404 **Functional Analysis of Outcome-Associated Proteins Reveals Immuno-Metabolic Pathway** 405 **Clusters**

406 We performed a network analysis of shared Reactome pathways (Figure 2A). Walktrap  
407 clustering revealed 4 major clusters of shared-pathway proteins (Table 2); Immune Regulation &  
408 Complement Activation, Metabolism, Protein Metabolism & Modification, and Cell Cycle. To  
409 validate our findings, we selected three representative proteins with available antibodies and  
410 known biological relevance (Vitronectin (VTN); fibrosis, Apolipoprotein E (APOE); CKD risk,

411 Cystatin C (CST3; nephron function) and confirmed that all three showed differences between  
412 low and high eGFR outcome sample subgroups by western blot (Figure 2B). Furthermore, all  
413 three proteins consistently predicted similar outcomes for each pair of kidneys within the triple-  
414 pair QC set, and correctly separated the two below-median outcome (eGFR<sub>12</sub><50) pairs from the  
415 above-median outcome (eGFR<sub>12</sub>>50) pair (Figure S6).

#### 416 **Association of Proteins with Posttransplant Outcome is Modulated by Donor Age**

417 For all 144 proteins, the minimal model retained an age:protein interaction term where  
418 the predictive effect of protein abundance was modulated by age, independent of the effect of  
419 age alone or protein abundance alone (Supplementary Table 2). To visualize these effects, we  
420 used each model to predict eGFR<sub>12</sub> across increasing donor age and protein quantile. The  
421 interplay between protein quantile and age could be broadly grouped (by hierarchical clustering)  
422 into 3 clusters with protein to eGFR<sub>12</sub> associations that showed different patterns across donor  
423 age (Figure 3), with about a third (31%) of candidates, including CST3, falling into a cluster with  
424 a profound effect of age on protein to eGFR<sub>12</sub> association at high donor age.

#### 425 **Comparison to Spatial scRNA-Seq Data Reveals Localization of Outcome-Associated** 426 **Signal**

427 As an independent validation of our findings, we sought to contextualize them in the  
428 wider context of kidney damage. To do this, we compared the expression levels of our candidate  
429 protein set to a recent spatial scRNA-seq dataset comparing AKI and CKD<sup>29</sup>. This initial  
430 comparison revealed that all 144 of our candidates were matched to transcripts reported in this  
431 external dataset, and, consistent with our proteomic data. Two of our highlighted candidates  
432 associated with outcomes, APOE and CST3, were also highlighted as associated with fibrosis  
433 and inflammation damaged tubules in this dataset.

434 We then investigated how the expression levels of transcripts corresponding to our set of  
435 144 proteins changed between AKI and CKD. We reasoned that protein and gene expression  
436 data that carries outcome-predictive information must reflect differences in organ injury.  
437 Therefore, between different injurious scenarios, we would expect gene expression that is  
438 predictive (i.e. discriminatory) to have lower correlation than genes whose expression change  
439 was linked to general inflammation and stress response. We compared the AKI:CKD expression  
440 correlation of our set of candidates versus the expression correlation of all other transcripts in the  
441 dataset. Since the dataset is spatially resolved, we were able to make this comparison across  
442 regions of the nephron. We observed that our candidate protein set had stronger discriminatory  
443 power (i.e. significantly lower correlation; Fisher test,  $p=4.04e-11$ ) than background in distal  
444 convoluted tubule epithelial cells and in surrounding structures, but not in leukocytes or in  
445 globally aggregated data (Figure 4).

446 This result gave us confidence that the 144-candidate set we report represents signatures  
447 of specific organ injury, and suggests that proteomic signals in distal convoluted tubule may be  
448 particularly representative of the extent to which injury impacts future functionality.

## 449 **DISCUSSION**

450 This study presents the first large unbiased human kidney tissue proteomics dataset for  
451 deceased donor kidneys. We examined the relationship between posttransplant kidney function  
452 with pretransplant kidney proteomes by analyzing 185 deceased donor kidneys with complete  
453 donor and recipient associated metadata. Although our study was not aiming to report a single  
454 biomarker, our large cohort, our unique machine learning approach, and finally alignment of  
455 proteomic data with a large spatial single cell transcriptomics dataset on healthy and diseased  
456 kidney substantiates our key findings. We describe an integration of kidney proteome with

457 clinical metadata and show that modelling age modulation of proteomic signals provides  
458 enhanced resolution of donor kidney quality stratification and highlights biological mechanisms.

459 Our analysis reveals the importance of integrating across both subclinical and clinical  
460 data. Exploring our data using iterative PRE feature selection, a substantial number of proteins  
461 were revealed to be relevant, but only one clinical variable, donor age. Donor age is a key  
462 contributor in clinical decisions and is a strongly weighted term in extant kidney allocation  
463 scoring systems<sup>8,33</sup>, but in the case of all reported candidate proteins, prediction models retained  
464 a protein:donor age interaction term. This second-order effect has not (to our knowledge) been  
465 explored in transplantation, and may be important to fully understanding molecular predictors.

466 A clinical variable notable by its omission from our association findings was donor  
467 type<sup>34</sup>. It is possible that outcome-predictive information ‘carried’ by donor type is also derivable  
468 from the proteome (proteomic data were able to partially distinguish samples based on type even  
469 when considering only variance across linear combinations of proteins; Figure S4). Without  
470 disputing donor type-specific mechanisms of kidney damage<sup>35</sup>, our data are consistent with the  
471 idea that location and type of damage may be a greater contributor towards recovery potential<sup>36</sup>  
472 than mechanism of injury.

473 Kidney metabolism is altered as a result of biological stress occurring during donor  
474 management, in both DBDs and DCDs<sup>37</sup>. Within our final list of 144 proteins associated with  
475 outcome there is a common theme of implication in immune response to kidney injury (including  
476 both chronic injury, and acute injury) as a result of metabolic disruption, particularly responses  
477 associated with ischemia. We highlighted three proteins from our set of 144 outcome-associated  
478 candidates as a sanity check; all three are examples of known chronic damage indicators that we  
479 find here to have a donor organ pre-transplant predictive association.

480 Vitronectin (VTN) is a primary component of the extracellular matrix involved in cell  
481 adhesion, enhancing the activity of plasminogen activator inhibitor-1 and inhibition of the  
482 terminal complement pathway<sup>38</sup>, and is a potential fibrotic biomarker<sup>39</sup>.

483 Apolipoprotein E (APOE) stands out as having previously reported genetic allele age-  
484 related associations with disease and organ dysfunction including risk of Alzheimer's Disease<sup>40</sup>  
485 (with the strongest effect manifesting around age 65<sup>41</sup>), macular dysfunction, atherosclerosis and  
486 pulmonary scarring<sup>42,43</sup>, and evidence for shared allele risk across diseases<sup>44</sup>. In kidneys, APOE  
487 plays an important role in lipid metabolism to regulate the growth and survival of mesangial cells  
488 and preserve organ function<sup>45</sup>; it is a marker for outcome in transplant recipients<sup>46-48</sup>, and there is  
489 evidence for *APOE* genotype association with kidney dysfunction risk<sup>49-51</sup>, possibly manifested  
490 by lipidomic differences between allelic profiles<sup>52</sup>. We have previously reported small (not  
491 statistically significant) increases in APOE due to ischemic reperfusion injuries<sup>53</sup> possibly  
492 explained by a role in senescence mediation<sup>54</sup>. There is existing evidence for similar allele  
493 dependent transplant outcome effects in another apolipoprotein (APOL1)<sup>55</sup>, suggesting that both  
494 *APOE* genotype and the broader apolipoprotein allelic profile may play an important role in  
495 posttransplant graft function.

496 Cystatin C (CST3) is particularly noteworthy as, measured in serum, it is a known and  
497 effective general biomarker for kidney function and has predictive power for outcomes in  
498 transplant recipients<sup>56-58</sup>. Our evidence indicates a further association between CST3 levels in  
499 donor kidney tissue and outcome; moreover, that this effect is age dependent, starting around age  
500 40. Serum CST3 is relatively independent of age in children and young adults<sup>59</sup>, but may also  
501 show age association in later years<sup>60</sup>.

502           A potential hurdle in contextualizing our findings in existing orthogonal transcriptomic  
503 data was that proteomes and transcriptomes are generally poorly correlated in terms of  
504 abundance changes<sup>61</sup>. In order to avoid this problem, we considered how the pattern of injury  
505 scenario-related differences changed between predictive and background signals within the same  
506 transcriptomic dataset<sup>29</sup>. The spatial component of this dataset further allowed us to show that  
507 injury-specific signals within our 144-protein set localized most strongly to the distal convoluted  
508 tubule (DCT) epithelium. Damage to DCT epithelial cells can be predictive of outcome<sup>62</sup>; the  
509 interplay of proximal and distal injury is complex<sup>63</sup>, but previous work has suggested that DCT  
510 epithelial cells can play an important protective and damage repair role across the nephron,  
511 expressing survival and reparative factors in response to injury<sup>64</sup>. Indications that aging is  
512 associated with accumulation of senescent epithelial cells with a maladaptive stress response<sup>29</sup>  
513 suggest a mechanism whereby aging related senescent cell accumulation could reduce the ability  
514 of DCT epithelia cells to protect and promote recovery of injury sustained by the proximal  
515 tubules. This would be consistent with our findings (immuno-metabolic and ischemia response  
516 functional association, and spatially localized response) and the negative donor age correlation  
517 with transplant outcome, and might explain recent successes with senescence inhibitors in  
518 treating CKD<sup>65</sup>, suggesting that routes to stimulate or enhance the DCT regenerative effect could  
519 be avenues for organ preservation.

520           Our list of outcome-associated candidates cannot be exhaustive. Practicalities of sample  
521 acquisition limited sampling of a wide range of outcomes outside the 30-60 donor age range,  
522 especially limited Upper Tertile outcome events in older donors. Organ allocation algorithms  
523 impose a close link between donor and recipient age in the sample cohort, so while we interpret  
524 these age-moderated effects in terms of organ resilience in older donors, it could also represent a



525 greater ability to repair a given level of damage in younger recipients. Further, we consider only  
526 chronological donor age, rather than a more nuanced representation of the epigenomic biological  
527 clock<sup>66</sup>, which may account for some variation observed with respect to both donors and  
528 recipients.

529 It is immediately clear from our results that the strength of the donor age factor is  
530 enormous relative to any other protein or clinical effect; this age effect is liable to dominate any  
531 prediction weighting and reduce the accuracy of estimated protein contribution. A much larger  
532 cohort could mitigate this issue, especially if paired with variant sequencing to understand  
533 genetic diversity. Advances in high-throughput proteomics techniques continue to increase  
534 feasible cohort sizes<sup>67</sup> but fundamental limitations on organ acquisition remain. Archiving at  
535 scale of clinical samples in bioresources such as the QUOD biobank to parallel advancements in  
536 big data analysis and interpretation platforms is therefore necessary for future development of  
537 granular evidence-based decision making.

538 However, given the limitations of our dataset, our protein models generalized well to  
539 samples unseen during model training (Figure S5), and showed promise for outcome-  
540 classification prediction (Figure S6) suggesting that, with a larger training cohort to address the  
541 caveats acknowledged above, a substantial component of early posttransplant outcome may be  
542 predictable solely using subclinical measurements moderated by donor age. The biological  
543 themes of the 144 proteins identified herein reinforce known immuno-metabolic mechanisms of  
544 kidney injury but raise interesting possibilities for further work, especially with regard to donor  
545 genetic background, and also suggest that the possibility of donor age-moderated weighting  
546 should be considered as a matter of course in future work.

547

548 **SUPPLEMENTARY MATERIALS**

549 Supplementary Table ST1: Clinical variable p-values for association with donor type and  
550 outcome.

551 Supplementary Table ST2: Summary of results for all candidate proteins.

552 Note that coefficient values provided are for linearized eGFR12, i.e. they relate to  
553 eGFR12 quantile ranging from 0 to 1.

554 Supplementary Figure S1: Donor and recipient clinical and demographic data association with  
555 recipient 12-month eGFR rank.

556 Single-linkage hierarchical clustering of curated, imputed clinical variables by relative  
557 association strength (taking distance as 1-association). The outcome variable (ranked  
558 recipient eGFR at 12 months post-transplantation) is highlighted in red.

559 Supplementary Figure S2: Protein quantification quality.

560 A: Missingness comparison: Proteins are shown ranked by the number of missing values  
561 across all samples and the twenty standard pools, excluding one run which was removed  
562 due to low signal. 2984 proteins had missing values in 50% or less runs.

563 B: Paired Kidney Comparison: Protein abundance values from paired kidneys (left/right)  
564 from 3 individual donors were compared, as these are effectively biological replicates. x  
565 axes: value in left kidney. y axes: value in right kidney. Inset: Pearson's r correlation  
566 coefficient.

567 Supplementary Figure S3: Scree plot of variance represented by the first ten principle  
568 components in the proteomic data.

569 A reasonable number for the cluster parameter (k) supplied for k-means clustering (see  
570 Figure S4) lay between 3 and 5 based on the 'elbow' method'; we selected k=4.

571 Supplementary Figure S4: Unbiased analysis of pretransplant kidney proteomes and cluster  
572 associations.

573 A: Unbiased analysis of proteomic data by k-means clustering. Sample separation by  
574 Principal Component Analysis. Top Left: Samples were assigned to four clusters by k-  
575 means. Bottom & Right: There was a difference in the distribution of DBD and DCD  
576 donors across clusters, with the DBD donors being more heavily concentrated in Cluster  
577 2 ('+' symbol; orange shading), and DCD in Cluster 4 ('x' symbol; pink shading)  
578 B: There were no associations between proteome clusters and most donor and recipient  
579 factors, except for mildly significant differences in donor BMI and creatinine (selected  
580 comparisons shown; left-right, top-bottom: donor type, recipient 12-month posttransplant  
581 eGFR (outcome), donor eGFR, donor age, donor BMI, donor creatinine at retrieval).

582 Supplementary Figure S5: Performance of individual protein with age models on unseen data.

583 For each protein, the protein term plus age term and protein:age interaction term were  
584 modelled against linearized 12-month posttransplant eGFR (eGFR12) using LASSO. For  
585 proteins passing filtering, with eGFR root-mean-square error (RMSE) better than an age-  
586 only model, we compared the RMSE achieved on the model training data against the  
587 RMSE achieved on held-out test data. We observed that the models actually achieved  
588 slightly better performance on the test data, reassuring us that no model was over-fit to  
589 the training data (i.e. all models generalized well to unseen data).

590 Supplementary Figure S6: Performance of VTN, APOE and CST3 models on paired kidney data.

591 Six of the analyzed kidneys were paired (i.e. two came from each of three donors). These  
592 data were not used for training or testing but reserved for QC of the proteomics (Figure  
593 S2). Although our analysis was focused on identification of outcome-associated protein

594 signals rather than prediction of eGFR12 (due to cohort size limitations, we do not claim  
595 to have a maximally biologically representative training set), we nevertheless used these  
596 paired kidneys to assess the consistency of our modelling in predicting above/below  
597 median outcomes in the three proteins we highlighted as particularly interesting. In all  
598 three pair cases the outcomes in (different) recipients were similar within each pair, and  
599 for all three proteins the model consistently predicted the correct above/below median  
600 classification for all six kidneys.

601

## 602 **DATA AND MATERIALS AVAILABILITY**

603 The mass spectrometry proteomics data have been deposited to the ProteomeXchange  
604 Consortium via the PRIDE <sup>68</sup> partner repository with the dataset identifier PXD033428.

605

## 606 **DISCLOSURE AND FUNDING**

607 This study was supported by NHS Blood and Transplant funding awarded to MK & RJP. SF was  
608 supported by Kidney Research UK, grant reference KS\_RP\_002\_20210111 awarded to MK.

609 PDC was supported by a Chinese Academy of Medical Sciences 2018-I2M-2-002 awarded to

610 BMK. Authors declare that they have no competing interests.

## 611 **Author contributions:**

612 Conceptualization: MK

613 Methodology: PDC, SF, RV, SD, RF, BMK, AS, ES, RJP, MK

614 Investigation: PDC, SF, RV, PJ, SD, IV, KT, AS

615 Visualization: PDC

616 Funding acquisition: BMK, RJP, MK  
617 Project oversight: MK  
618 Supervision: RF, AS, MK  
619 Writing – original draft: PDC, ES, MK  
620 Writing – review & editing: All authors

621

## 622 REFERENCES

- 623 1. Callaghan CJ, Mumford L, Pankhurst L, Baker RJ, Bradley JA, Watson CJE. Early  
624 Outcomes of the New UK Deceased Donor Kidney Fast-Track Offering Scheme.  
625 *Transplantation*. 2017;101(12):2888-2897. doi:10.1097/TP.0000000000001860
- 626 2. Summers DM, Johnson RJ, Hudson AJ, et al. Standardized deceased donor kidney donation  
627 rates in the UK reveal marked regional variation and highlight the potential for increasing  
628 kidney donation: a prospective cohort study†. *Br J Anaesth*. 2014;113(1):83-90.  
629 doi:10.1093/bja/aet473
- 630 3. Denic A, Glassock RJ, Rule AD. The Kidney in Normal Aging: A Comparison with Chronic  
631 Kidney Disease. *Clin J Am Soc Nephrol*. 2022;17(1):137-139. doi:10.2215/CJN.10580821
- 632 4. O’Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. *J*  
633 *Am Soc Nephrol*. 2007;18(10):2758-2765. doi:10.1681/ASN.2007040422
- 634 5. Ishani A, Xue JL, Himmelfarb J, et al. Acute Kidney Injury Increases Risk of ESRD among  
635 Elderly. *J Am Soc Nephrol*. 2009;20(1):223-228. doi:10.1681/ASN.2007080837
- 636 6. Summers DM, Johnson RJ, Hudson A, Collett D, Watson CJ, Bradley JA. Effect of donor  
637 age and cold storage time on outcome in recipients of kidneys donated after circulatory death  
638 in the UK: a cohort study. *Lancet*. 2013;381(9868):727-734. doi:10.1016/S0140-  
639 6736(12)61685-7
- 640 7. Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for  
641 deceased donor kidneys: the kidney donor risk index. *Transplantation*. 2009;88(2):231-236.  
642 doi:10.1097/TP.0b013e3181ac620b
- 643 8. Watson CJE, Johnson RJ, Birch R, Collett D, Bradley JA. A Simplified Donor Risk Index  
644 for Predicting Outcome After Deceased Donor Kidney Transplantation. *Transplantation*.  
645 2012;93(3):314-318. doi:10.1097/TP.0b013e31823f14d4
- 646 9. Neuberger J, Callaghan C. Organ utilization - the next hurdle in transplantation? *Transpl Int*.  
647 2020;33(12):1597-1609. doi:10.1111/tri.13744

- 648 10. Clayton PA, Dansie K, Sypek MP, et al. External validation of the US and UK kidney donor  
649 risk indices for deceased donor kidney transplant survival in the Australian and New Zealand  
650 population. *Nephrol Dial Transplant*. 2019;34(12):2127-2131. doi:10.1093/NDT/GFZ090
- 651 11. Yu K, Husain SA, King K, Stevens JS, Parikh CR, Mohan S. Kidney nonprocurement in  
652 deceased donors with acute kidney injury. *Clin Transplant*. Published online August 4,  
653 2022:e14788. doi:10.1111/ctr.14788
- 654 12. Hall IE, Akalin E, Bromberg JS, et al. Deceased-donor acute kidney injury is not associated  
655 with kidney allograft failure. *Kidney Int*. 2019;95(1):199-209.  
656 doi:10.1016/j.kint.2018.08.047
- 657 13. Liu C, Hall IE, Mansour S, Thiessen Philbrook HR, Jia Y, Parikh CR. Association of  
658 Deceased Donor Acute Kidney Injury With Recipient Graft Survival. *JAMA Network Open*.  
659 2020;3(1):e1918634. doi:10.1001/jamanetworkopen.2019.18634
- 660 14. Mansour SG, Khoury N, Kodali R, et al. Clinically adjudicated deceased donor acute kidney  
661 injury and graft outcomes. *PLoS One*. 2022;17(3):e0264329.  
662 doi:10.1371/journal.pone.0264329
- 663 15. von Moos S, Akalin E, Mas V, Mueller TF. Assessment of Organ Quality in Kidney  
664 Transplantation by Molecular Analysis and Why It May Not Have Been Achieved, Yet.  
665 *Front Immunol*. 2020;11:833. doi:10.3389/fimmu.2020.00833
- 666 16. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated  
667 by data-independent acquisition: a new concept for consistent and accurate proteome  
668 analysis. *Mol Cell Proteomics*. 2012;11(6):O111.016717. doi:10.1074/mcp.O111.016717
- 669 17. Geyer PE, Holdt LM, Teupser D, Mann M. Revisiting biomarker discovery by plasma  
670 proteomics. *Mol Syst Biol*. 2017;13(9):942. doi:10.15252/msb.20156297
- 671 18. Connor KL, O'Sullivan ED, Marson LP, Wigmore SJ, Harrison EM. The Future Role of  
672 Machine Learning in Clinical Transplantation. *Transplantation*. 2021;105(4):723-735.  
673 doi:10.1097/TP.0000000000003424
- 674 19. Raynaud M, Aubert O, Divard G, et al. Dynamic prediction of renal survival among deeply  
675 phenotyped kidney transplant recipients using artificial intelligence: an observational,  
676 international, multicohort study. *The Lancet Digital Health*. 2021;3(12):e795-e805.  
677 doi:10.1016/S2589-7500(21)00209-0
- 678 20. Demichev V, Messner CB, Vernardis SI, Lilley KS, Ralser M. DIA-NN: neural networks  
679 and interference correction enable deep proteome coverage in high throughput. *Nat Methods*.  
680 2020;17(1):41-44. doi:10.1038/s41592-019-0638-x
- 681 21. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M. Variance stabilization  
682 applied to microarray data calibration and to the quantification of differential expression.  
683 *Bioinformatics*. 2002;18(Suppl 1):S96-S104. doi:10.1093/bioinformatics/18.suppl\_1.S96
- 684 22. Hastie T, Tibshirani R, Narasimhan B, Chu G. *Impute: Imputation for Microarray Data.*;  
685 2021. <http://www.bioconductor.org/packages/release/bioc/html/impute.html>

- 686 23. Fokkema M. Fitting prediction rule ensembles with R package pre. *J Stat Softw.*  
687 2020;92(1):1-30. doi:10.18637/jss.v092.i12
- 688 24. Milborrow. Derived from mda:mars by T. Hastie and R. Tibshirani. *S. Earth: Multivariate*  
689 *Adaptive Regression Splines.*; 2011. <http://CRAN.R-project.org/package=earth>
- 690 25. Jawaid W. *EnrichR: Provides an R Interface to "Enrichr."*; 2021. [https://cran.r-](https://cran.r-project.org/package=enrichR)  
691 [project.org/package=enrichR](https://cran.r-project.org/package=enrichR)
- 692 26. Csárdi G, Nepusz T. The igraph software package for complex network research.  
693 *InterJournal.* 2006;Complex Systems:1695.
- 694 27. Pons P, Latapy M. *Computing Communities in Large Networks Using Random Walks.*  
695 (Yolum P, Güngör T, Gürgen F, Özturan C, eds.). Springer; 2005. doi:10.1007/11569596\_31
- 696 28. Trucios C. *StatPerMeCo: Statistical Performance Measures to Evaluate Covariance Matrix*  
697 *Estimates.*; 2017. <https://CRAN.R-project.org/package=StatPerMeCo>
- 698 29. Lake BB, Menon R, Winfree S, et al. An atlas of healthy and injured cell states and niches in  
699 the human kidney. *Nature.* 2023;619(7970):585-594. doi:10.1038/s41586-023-05769-3
- 700 30. Fisher RA. *Statistical Methods for Research Workers.* Oliver and Boyd; 1925.  
701 <https://openlibrary.org/books/OL17638383M.opds>
- 702 31. Diedenhofen B, Musch J. cocor: A Comprehensive Solution for the Statistical Comparison  
703 of Correlations. *PLoS ONE.* 2015;10(4):e0121945. doi:10.1371/journal.pone.0121945
- 704 32. Friedman JH, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models  
705 via Coordinate Descent. *J Stat Softw.* 2010;33:1-22. doi:10.18637/jss.v033.i01
- 706 33. Li B, Cairns JA, Robb ML, et al. Predicting patient survival after deceased donor kidney  
707 transplantation using flexible parametric modelling. *BMC Nephrol.* 2016;17(1):51.  
708 doi:10.1186/s12882-016-0264-0
- 709 34. Gill J, Rose C, Lesage J, Joffres Y, Gill J, O'Connor K. Use and Outcomes of Kidneys from  
710 Donation after Circulatory Death Donors in the United States. *J Am Soc Nephrol.*  
711 2017;28(12):3647-3657. doi:10.1681/asn.2017030238
- 712 35. Vaughan RH, Kresse JC, Farmer LK, et al. Cytoskeletal protein degradation in brain death  
713 donor kidneys associates with adverse post-transplant outcomes. *Am J Transplant.* Published  
714 online December 8, 2021. doi:10.1111/ajt.16912
- 715 36. Kosmoliaptsis V, Salji M, Bardsley V, et al. Baseline donor chronic renal injury confers the  
716 same transplant survival disadvantage for DCD and DBD kidneys. *Am J Transplant.*  
717 2015;15(3):754-763. doi:10.1111/ajt.13009
- 718 37. Damman J, Bloks VW, Daha MR, et al. Hypoxia and Complement-and-Coagulation  
719 Pathways in the Deceased Organ Donor as the Major Target for Intervention to Improve  
720 Renal Allograft Outcome. *Transplantation.* 2015;99(6):1293-1300.  
721 doi:10.1097/TP.0000000000000500

- 722 38. De Lorenzi V, Sarra Ferraris GM, Madsen JB, Lupia M, Andreasen PA, Sidenius N.  
723 Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in  
724 vitronectin. *EMBO Rep.* 2016;17(7):982-998. doi:10.15252/embr.201541681
- 725 39. Carreras-Planella L, Cucchiari D, Cañas L, et al. Urinary vitronectin identifies patients with  
726 high levels of fibrosis in kidney grafts. *J Nephrol.* 2021;34(3):861-874. doi:10.1007/s40620-  
727 020-00886-y
- 728 40. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk,  
729 mechanisms, and therapy. *Nat Rev Neurol.* 2013;9(2):106-118.  
730 doi:10.1038/nrneurol.2012.263
- 731 41. Saddiki H, Fayosse A, Cognat E, et al. Age and the association between apolipoprotein E  
732 genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.  
733 *PLoS Med.* 2020;17(8):e1003289. doi:10.1371/journal.pmed.1003289
- 734 42. Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. *Annu Rev*  
735 *Genomics Hum Genet.* 2000;1:507-537. doi:10.1146/annurev.genom.1.1.507
- 736 43. Yao X, Gordon EM, Figueroa DM, Barochia AV, Levine SJ. Emerging Roles of  
737 Apolipoprotein E and Apolipoprotein A-I in the Pathogenesis and Treatment of Lung  
738 Disease. *Am J Respir Cell Mol Biol.* 2016;55(2):159-169. doi:10.1165/rcmb.2016-0060TR
- 739 44. Miwa K, Tanaka M, Okazaki S, et al. Chronic kidney disease is associated with dementia  
740 independent of cerebral small-vessel disease. *Neurology.* 2014;82(12):1051-1057.  
741 doi:10.1212/WNL.0000000000000251
- 742 45. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S. A Protective Role for Kidney  
743 Apolipoprotein E: REGULATION OF MESANGIAL CELL PROLIFERATION AND  
744 MATRIX EXPANSION. *J Biol Chem.* 2001;276(52):49142-49147.  
745 doi:10.1074/JBC.M104879200
- 746 46. Kahraman S, Kiykim AA, Altun B, et al. Apolipoprotein E gene polymorphism in renal  
747 transplant recipients: effects on lipid metabolism, atherosclerosis and allograft function. *Clin*  
748 *Transplant.* 2004;18(3):288-294. doi:10.1111/j.1399-0012.2004.00162.x
- 749 47. Hernández D, Salido E, Linares J, et al. Role of apolipoprotein E epsilon 4 allele on chronic  
750 allograft nephropathy after renal transplantation. *Transplant Proc.* 2004;36(10):2982-2984.  
751 doi:10.1016/j.transproceed.2004.10.038
- 752 48. Cofán F, Cofan M, Rosich E, et al. Effect of apolipoprotein E polymorphism on renal  
753 transplantation. *Transplant Proc.* 2007;39(7):2217-2218.  
754 doi:10.1016/j.transproceed.2007.06.011
- 755 49. Czaplínska M, Ćwiklińska A, Sakowicz-Burkiewicz M, et al. Apolipoprotein e gene  
756 polymorphism and renal function are associated with apolipoprotein e concentration in  
757 patients with chronic kidney disease. *Lipids Health Dis.* 2019;18(1):1-9.  
758 doi:10.1186/s12944-019-1003-x



- 759 50. Hsu CC, Kao WHL, Coresh J, et al. Apolipoprotein E and progression of chronic kidney  
760 disease. *J Am Med Assoc.* 2005;293(23):2892-2899. doi:10.1001/jama.293.23.2892
- 761 51. Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Etiological significance of apolipoprotein E  
762 mutations in lipoprotein glomerulopathy. *Trends Cardiovasc Med.* 2002;12(2):67-70.  
763 doi:10.1016/S1050-1738(01)00148-7
- 764 52. Sienski G, Narayan P, Bonner JM, et al. APOE4 disrupts intracellular lipid homeostasis in  
765 human iPSC-derived glia. *Sci Transl Med.* 2021;13(583):eaaz4564.  
766 doi:10.1126/scitranslmed.aaz4564
- 767 53. Huang H, van Dullemen LFA, Akhtar MZ, et al. Proteo-metabolomics reveals compensation  
768 between ischemic and non-injured contralateral kidneys after reperfusion. *Sci Rep.*  
769 2018;8(1):8539. doi:10.1038/s41598-018-26804-8
- 770 54. Zhao H, Ji Q, Wu Z, et al. Destabilizing heterochromatin by APOE mediates senescence.  
771 *Nature Aging.* 2022;2(4):303-316. doi:10.1038/s43587-022-00186-z
- 772 55. Julian BA, Gaston RS, Brown WM, et al. Effect of Replacing Race with Apolipoprotein L1  
773 Genotype in Calculation of Kidney Donor Risk Index. *Am J Transplant.* 2017;17(6):1540.  
774 doi:10.1111/AJT.14113
- 775 56. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive  
776 estimation of glomerular filtration rate and as a marker for early renal impairment. *Am J*  
777 *Kidney Dis.* 2000;36(1):29-34. doi:10.1053/ajkd.2000.8237
- 778 57. Christensson A, Ekberg J, Grubb A, Ekberg H, Lindström V, Lilja H. Serum cystatin C is a  
779 more sensitive and more accurate marker of glomerular filtration rate than enzymatic  
780 measurements of creatinine in renal transplantation. *Nephron Physiol.* 2003;94(2):19-27.  
781 doi:10.1159/000071287
- 782 58. Rodrigo E, Ruiz JC, Fernández-Fresnedo G, et al. Cystatin C and albuminuria as predictors  
783 of long-term allograft outcomes in kidney transplant recipients. *Clin Transplant.*  
784 2013;27(2):E177-83. doi:10.1111/ctr.12082
- 785 59. Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C--a  
786 new marker of glomerular filtration rate in children independent of age and height.  
787 *Pediatrics.* 1998;101(5):875-881. doi:10.1542/peds.101.5.875
- 788 60. Edinga-Melenge BE, Yakam AT, Nansseu JR, et al. Reference intervals for serum cystatin C  
789 and serum creatinine in an adult sub-Saharan African population. *BMC Clin Pathol.*  
790 2019;19:4. doi:10.1186/s12907-019-0086-7
- 791 61. Cox J, Mann M. 1D and 2D annotation enrichment: a statistical method integrating  
792 quantitative proteomics with complementary high-throughput data. *BMC Bioinformatics.*  
793 2012;13(16):S12. doi:10.1186/1471-2105-13-S16-S12
- 794 62. Oberbauer R, Rohrmoser M, Regele H, Mühlbacher F, Mayer G. Apoptosis of tubular  
795 epithelial cells in donor kidney biopsies predicts early renal allograft function. *J Am Soc*  
796 *Nephrol.* 1999;10(9):2006-2013. doi:10.1681/ASN.V1092006

- 797 63. Heyman SN, Rosenberger C, Rosen S. Experimental ischemia-reperfusion: biases and  
798 myths-the proximal vs. distal hypoxic tubular injury debate revisited. *Kidney Int.*  
799 2010;77(1):9-16. doi:10.1038/ki.2009.347
- 800 64. Gobe GC, Johnson DW. Distal tubular epithelial cells of the kidney: Potential support for  
801 proximal tubular cell survival after renal injury. *Int J Biochem Cell Biol.* 2007;39(9):1551-  
802 1561. doi:10.1016/j.biocel.2007.04.025
- 803 65. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin  
804 in Patients with Chronic Kidney Disease. *N Engl J Med.* 2023;388(2):117-127.  
805 doi:10.1056/NEJMoa2204233
- 806 66. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of  
807 ageing. *Nat Rev Genet.* 2018;19(6):371-384. doi:10.1038/s41576-018-0004-3
- 808 67. Meier F, Brunner AD, Frank M, et al. diaPASEF: parallel accumulation–serial fragmentation  
809 combined with data-independent acquisition. *Nat Methods.* 2020;17(12):1229-1236.  
810 doi:10.1038/s41592-020-00998-0
- 811 68. Perez-Riverol Y, Csordas A, Bai J, et al. The PRIDE database and related tools and  
812 resources in 2019: improving support for quantification data. *Nucleic Acids Res.*  
813 2019;47(D1):D442-D450. doi:10.1093/nar/gky1106


814

## 815 **ACKNOWLEDGMENTS**

816 We thank the UK QUOD Consortium and NHS Blood and Transplant UK Registry for providing  
817 the samples and the associated clinical and demographic metadata. ; in particular we thank Sheba  
818 Ziyenge, Lewis Simmonds and Dr Sarah Cross, Dr Sergei Maslau and Mr Tomas Surik for their  
819 support on the QUOD sample selection.

820 We thank members of the Discovery Proteomics Facility within the TDI Mass Spectrometry  
821 Laboratory for expert help with mass spectrometry analysis, and members of the Lindgren group  
822 at the BDI for informative discussions regarding statistical modelling.

823 **FIGURES AND TABLES**



824  
825 **Figure 1: Experimental design to discover donor kidney proteome associations with transplant outcome**  
826 We selected biopsies from QUOD biobank taken from one kidney from each donor pair. Donor kidney samples  
827 were selected randomly from pairs where both recipients had similar outcomes. The biopsy samples were subjected  
828 to proteomic analysis to yield a snapshot of the organ proteome at kidney retrieval. We analyzed donor  
829 characteristics and clinical variables and protein abundances in a combined model against recipient eGFR at 12  
830 months posttransplant (eGFR12; units given in  $\text{ml}/\text{min}/1.73 \text{ m}^2$ ).

Donor Type	DBD			DCD		
12m Outcome Tertile <i>ml/min/1.73 m<sup>2</sup></i>	Lower <i>eGFR&lt;40</i>	Intermediate <i>40≤eGFR&lt;60</i>	Upper <i>eGFR≥60</i>	Lower <i>eGFR&lt;40</i>	Intermediate <i>40≤eGFR≤60</i>	Upper <i>eGFR≥60</i>
n	31	31	38	31	28	26
Donor Age, y	56.84 ± 12.29	51.32 ± 12.24	39.05 ± 14.12	55.48 ± 9.34	53.57 ± 9.75	38.31 ± 12.28
Donor Sex						
Male	15 (48.4%)	16 (51.6%)	19 (50.0%)	22 (71.0%)	16 (57.1%)	16 (61.5%)
Female	16 (51.6%)	15 (48.4%)	19 (50.0%)	9 (29.0%)	12 (42.9%)	10 (38.5%)
Donor Ethnicity						
White	30 (96.8%)	30 (96.8%)	36 (94.7%)	30 (96.8%)	28 (100.0%)	25 (96.2%)
Other	1 (3.2%)	1 (3.2%)	2 (5.3%)	1 (3.2%)	0 (0.0%)	1 (3.8%)
Donor Weight, kg	82.53 ± 18.20	76.61 ± 18.07	81.38 ± 17.72	80.58 ± 14.95	82.43 ± 17.20	78.67 ± 13.96
Donor Height, cm	168.42 ± 9.37	169.52 ± 7.67	174.82 ± 11.16	169.97 ± 7.98	171.64 ± 9.73	174.65 ± 8.98
Donor S-Cr terminal, μmol/l	86.54 ± 40.81	82.57 ± 49.65	90.19 ± 67.36	73.37 ± 19.03	70.31 ± 39.02	59.60 ± 22.39
Donor CIT, h	15.80 ± 3.88	14.20 ± 4.60	13.42 ± 4.67	13.65 ± 5.20	11.72 ± 3.55	12.80 ± 4.49
Donor COD						
Trauma	1 (3.2%)	3 (9.7%)	3 (7.9%)	4 (12.9%)	3 (10.7%)	4 (15.4%)
Other	30 (96.8%)	28 (90.3%)	35 (92.1%)	27 (87.1%)	25 (89.3%)	22 (84.6%)
Donor UKKDRI	1.41 ± 0.52	1.10 ± 0.36	0.85 ± 0.36	1.31 ± 0.37	1.21 ± 0.40	0.73 ± 0.35
Recipient Age, y	53.03 ± 12.21	52.10 ± 14.61	39.71 ± 16.03	51.90 ± 9.85	50.93 ± 11.04	44.92 ± 12.87
Recipient Sex						
Female	15 (48.4%)	8 (25.8%)	12 (31.6%)	11 (35.5%)	9 (32.1%)	5 (19.2%)
Male	16 (51.6%)	23 (74.2%)	26 (68.4%)	20 (64.5%)	19 (67.9%)	21 (80.8%)
Recipient Ethnicity						
White	24 (77.4%)	21 (67.7%)	29 (76.3%)	22 (71.0%)	23 (82.1%)	20 (76.9%)
Other	7 (22.6%)	10 (32.3%)	9 (23.7%)	9 (29.0%)	5 (17.9%)	6 (23.1%)
Recipient Posttransplant Kidney Function (mean eGFR, ml/min/1.73 m <sup>2</sup> )						
3 months	29.71 ± 12.06	50.32 ± 17.28	78.54 ± 25.97	31.72 ± 12.24	46.50 ± 10.34	77.88 ± 18.57
12 months	26.58 ± 11.98	49.58 ± 6.10	85.58 ± 35.84	25.10 ± 12.01	48.24 ± 6.29	80.26 ± 15.91
HLA Mismatch Groups						
0 Mismatches	3 (10.0%)	4 (11.4%)	9 (25.7%)	1 (2.9%)	1 (4.2%)	0 (0.0%)
0 DR and 0/1 B	7 (23.3%)	13 (37.1%)	10 (28.6%)	10 (28.6%)	6 (25.0%)	8 (30.8%)
0 DR and 2 B or 1 DR and 0/1 B	17 (56.7%)	14 (40.0%)	13 (37.1%)	21 (60.0%)	14 (58.3%)	14 (53.8%)
1 DR and 2 B or 2 DR	3 (10.0%)	4 (11.4%)	3 (8.6%)	3 (8.6%)	3 (12.5%)	4 (15.4%)


831 **Table 1: Donor and recipient clinical and demographic variables**

832 Donor kidney associated metadata. Samples are subdivided by donor type and by final assigned outcome tertile.


833 Numerical variables are given  $\pm$  standard deviation. Categorical variables are given alongside percentage of total

834 cohort

**A**



**B**



836 **Figure 2: Proteins predicting transplant outcome show immuno-metabolic functional associations, predict**  
837 **low eGFR outcomes and are consistent with Western Blot assay results.**

838 A: Shared Reactome pathway membership network analysis of filtered features. Nodes are colored by assigned  
839 cluster, and the clusters are annotated according to the top three most enriched pathways within each cluster.

840 B: Western blots comparing younger (age  $\leq 49$ ; mean age 34) and older (age  $\geq 58$ ; mean age 64) donors between  
841 Upper Tertile (UT; eGFR12  $\geq 60$ ) and Lower Tertile (LT; eGFR12  $< 40$ ) outcomes. As above, Left-Right: VTN,  
842 APOE, CST3. Top row: representative western blots (n=5 per group) from comparison of younger donors. Middle  
843 row: representative western blots (n=5 per group) from comparison of older donors. Bottom row: result values for  
844 all quantified samples relative to the UT mean. UT values in green, LT values in blue. Error bars indicate  $\pm 1$   
845 standard deviation; the central wider bar indicates mean. Significance stars indicate t-test comparison p-values (\*\*\*:  
846  $p < 0.001$ , \*:  $p < 0.05$ ).


847 All eGFR12 units given in ml/min/1.73 m<sup>2</sup>

<b>Cluster Label</b>	<b>Top 3 Shared Pathways</b>
Immune Regulation & Complement Activation	Immune System Innate Immune System Regulation of Complement Cascade
Protein Metabolism and Regulation	Metabolism of Proteins Post-translational Protein Modification Post-translational Protein Phosphorylation
Metabolism	Metabolism Metabolism of Amino Acids and Derivatives Retinoid Metabolism and Transport
Cell Cycle	Cyclin E Associated Events During G1/S Transition Cyclin A:Cdk2-associated Events at S Phase Entry PCP/CE Pathway


848 **Table 2: Major Shared Pathway Network Clusters**

849 Proteins in Figure 2A were clustered by pathway membership, forming 4 major clusters (those with more than a  
850 single member). We assigned summary labels to each cluster based on the top 3 pathways with shared membership  
851 in each cluster.





852  
 853 **Figure 3: Modelled associations between proteins and kidney transplant outcome change with donor age**  
 854 Our modelling found that the effect of candidate protein levels on outcome changed with age.  
 855 A: We quantile-normalized protein levels to a consistent scale and predicted outcome (12-month posttransplant  
 856 eGFR) across a representative donor age range. Using this prediction matrix to compare the interaction with age  
 857 between protein models, we found 3 major clusters (Left-Right; blue, pink and green dendrogram branches and  
 858 corresponding plot background color) representing increasing levels of age modulation. Moving Left-Right across  
 859 each plot, the eGFR12 (color scale, see key on right) contours across protein quantile (y axis) change as donor age  
 860 (x axis) increases.  
 861 B: Illustrative protein quantile-GFR12 plots are shown for each three proteins in each cluster. Traces are shown for  
 862 donor ages between 20 and 80 as labelled on the right end of each trace.



863 **Figure 4: Independent scRNA-seq Data Indicate Spatial Localization of the Outcome-Associated Signature**  
864 We reasoned that proteins/genes which predict outcome should associate with specific facets of organ injury rather  
865 than general inflammatory and stress response, and therefore would be expected to have a *lower* expression  
866 correlation between acute and chronic damage scenarios than non-predictive other proteins/genes. We explored this  
867 in a spatially resolved public transcriptomic dataset and found that the degree of correlation was significantly lower  
868 for the set of 144 candidate predictors identified by our modelling approach, but that the signal appears to be  
869 spatially localized, primarily to distal convoluted tubule epithelial cells and the epithelia of neighboring tubules  
870 (indicated by red highlighting in right hand diagram).